Mylan NV (NASDAQ: MYL), a global pharmaceutical company, announced yesterday that it has launched its Medroxyprogesterone Acetate Injectable (MPA) Suspension USP, 150mg/mL Single-Dose Vial, a generic version of the brand drug, Pfizer's Depo-Provera, in the United States.
The company is providing the product, which is indicated in the prevention of pregnancy, to its institutional customers after an Abbreviated New Drug Application for the product was approved by the US Food and Drug Administration (FDA).
Mylan CEO, Heather Bresch, said, 'The launch of Medroxyprogesterone Acetate adds to Mylan's robust portfolio of generic birth control medicines in the US. These products are part of Mylan's growing women's healthcare offerings, which include a variety of medicines to help women manage their health across all the stages of their lives.'
US sales for MPA were approximately USD181 million for the 12 months ending 31 July 2018.
Amneal to unveil generic Isoproterenol Hydrochloride Injection USP in the US
Amneal passes US FDA approval for marketing Carmustine for Injection USP in 100 mg/vial
Mylan launches Medroxyprogesterone Acetate Injectable Suspension USP in US
Dr Reddy's Laboratories to divest Hyderabad API manufacturing business unit to Therapiva Private
Dr. Reddy's Laboratories divests API manufacturing business unit in Jeedimetla, Hyderabad, India
Breckenridge awarded US FDA approval for Roflumilast Tablets (Daliresp) ANDA
ANI Pharmaceuticals launches Candesartan Hydrochlorothiazide Tablets
Dr. Reddy's Laboratories Has Regained Worldwide Rights to DFA-02
Dr. Reddy's Laboratories Launches Imatinib Mesylate Tablets, USP in the US Market